Pasar al contenido principal

Inmunometabolismo e Inflamación

IJC2018-036850-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprograma Subprograma Estatal de Incorporación
Convocatoria Juan de la Cierva Incorporación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The role of T cells in age-related diseases

  • Carrasco, Elisa
  • Gómez de las Heras, Manuel M.
  • Gabandé-Rodríguez, Enrique
  • Desdín-Mico, Gabriela
  • Aranda, Juan Francisco
  • Mittelbrunn, María
Age-related T cell dysfunction can lead to failure of immune tolerance mechanisms, resulting in aberrant T cell-driven cytokine and cytotoxic responses that ultimately cause tissue damage. In this Review, we discuss the role of T cells in the onset and progression of age-associated conditions, focusing on cardiovascular disorders, metabolic dysfunction, neuroinflammation and defective tissue repair and regeneration. We present different mechanisms by which T cells contribute to inflammageing and might act as modulators of age-associated diseases, including through enhanced pro-inflammatory and cytotoxic activity, defective clearance of senescent cells or regulation of the gut microbiota. Finally, we propose that ‘resetting’ immune system tolerance or targeting pathogenic T cells could open up new therapeutic opportunities to boost resilience to age-related diseases., This study was supported by the Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI19/855), the European Regional Development Fund (ERDF) and the European Commission through H2020-EU.1.1, European Research Council grant ERC-2016-StG 715322-EndoMitTalk and the Madrid Government (Comunidad de Madrid-Spain) under the Multiannual Agreement with Universidad Autónoma de Madrid in the line of action encouraging youth research doctors, in the context of the V PRICIT (Regional Programme of Research and Technological Innovation) (SI1/PJI/2019-00073). M.M. is supported by the Miguel Servet Program (CP 19/014, Fundación de Investigación del Hospital 12 de Octubre). M.M.G.H. and E.G.-R. are supported by an FPU grant (FPU19/02576) and a Juan de la Cierva grant (IJC2018-036850-I), respectively, both from Ministerio de Ciencia, Innovación y Universidades (Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immuno(T)herapy for age-related diseases

  • Gabandé-Rodríguez, Enrique
  • Pfeiffer, Matilda
  • Mittelbrunn, María
During the last decade, the stimulation of T-cell function by the blockage of immunosuppressive checkpoints has experienced an outstanding impact in the treatment of cancer. Development of the chimeric antigen receptor T-cell technology has also emerged as a powerful alternative for patients suffering from oncological processes, especially those affected by hematological neoplasms. Recent evidence suggest that the use of immunotherapy could be extended to non-oncological diseases and could be especially relevant for age-associated disorders, opening exciting therapeutic options for a wide range of diseases of the elderly. Here we comment on the emergence of T-cell-based immunotherapies as feasible approaches that could revolutionize the future of GeroScience., Our laboratory is supported by the Fondo de Investigación Sanitaria del Instituto de Salud CarlosIII (PI19/855), the European Research Council grant ERC-2016-StG715322-EndoMitTalk, and Y2020/BIO-6350 NutriSION funded by Comunidad de Madrid. E.G.-R. is supported by a Juan de la Cierva-Incorporación grant (IJC2018-036850-I) from the Ministerio de Ciencia, Innovación y Universidades (Spain), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

CD4 T cell therapy counteracts inflammaging and senescence by preserving gut barrier integrity

  • Gómez de las Heras, Manuel M.
  • Carrasco, Elisa
  • Pérez-Manrique, Mario
  • Inohara, Naohiro
  • Delgado-Pulido, Sandra
  • Fernández-Almeida, Álvaro
  • Gálvez-Castaño, María I.
  • Francos-Quijorna, Isaac
  • Simó, Carolina
  • García-Cañas, Virginia
  • Escrig-Larena, Jose Ignacio
  • Aranda, Juan Francisco
  • Soto-Heredero, Gonzalo
  • Gabandé-Rodríguez, Enrique
  • Blanco, Eva M.
  • Días-Almeida, Joyce
  • Núñez, Gabriel
  • Mittelbrunn, María
Healthy aging relies on a symbiotic host–microbiota relationship. The age-associated decline of the immune system can pose a threat in this delicate equilibrium. In this work, we investigated how the functional deterioration of T cells can impact host–microbiota symbiosis and gut barrier integrity and the implications of this deterioration for inflammaging, senescence, and health decline. Using the Tfamfl/flCd4 Cre mouse model, we found that T cell failure compromised gut immunity leading to a decrease in T follicular and regulatory T (Treg) cells and an accumulation of highly proinflammatory and cytotoxic T cells. These alterations were associated with intestinal barrier disruption and gut dysbiosis. Microbiota depletion or adoptive transfer of total CD4 T cells or a Treg cell–enriched pool prevented gut barrier dysfunction and mitigated premature inflammaging and senescence, ultimately enhancing healthspan in this mouse model. Thus, a competent CD4 T cell compartment is critical to ensure healthier aging by promoting host–microbiota mutualism and gut barrier integrity., This research was supported by European Research Council grant ERC-2021-CoG 101044248-Let T Be (M.M.), Comunidad de Madrid (Spain) grant Y2020/BIO-6350 NutriSION-CM synergy (E.C. and M.M.), Spanish Ministerio de Ciencia e Innovación grant PID2022-141169OB-I00 (M.M.), Comunidad de Madrid (Spain) – Universidad Autónoma de Madrid (UAM) grant SI4/PJI/2024-00166 (E.C.), NIH grant R01 DK095782 (G.N.), Ministerio de Ciencia, Innovación y Universidades (Spain) FPU grants FPU19/02576 (M.M.G.H.), FPU22/01192 (M.P.-M.), and FPU20/04066 (J.I.E.-L.), Comunidad de Madrid (Spain) PIPF grant PIPF-2022/SAL-GL-25208 (S.D.-P.), Universidad Autónoma de Madrid FPI-UAM grant (G.S.-H.), and Ministerio de Ciencia, Innovación y Universidades (Spain) Juan de la Cierva-Incorporación grants IJC2018-036850-I (E.G.-R.) and JC2020-044392-I(I.F.-Q.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Butyrate extends health and lifespan in mice with mitochondrial deficiency

  • Gabandé-Rodríguez, Enrique
  • Gómez de las Heras, Manuel M.
  • Ramírez-Ruiz de Erenchun, Pablo
  • Simó, Carolina
  • García-Cañas, Virginia
  • Inohara, Naohiro
  • Berenguer-López, Inés
  • Enríquez-Zarralanga, Violeta
  • Fernández-Almeida, Álvaro
  • Oller, Jorge
  • Soto-Heredero, Gonzalo
  • Carrasco, Elisa
  • Vázquez-Muñoz, Cristina
  • Delgado-Pulido, Sandra
  • Escrig-Larena, Jose Ignacio
  • Francos-Quijorna, Isaac
  • Justo-Méndez, Raquel
  • Aranda, Juan Francisco
  • Poulton, Joanna
  • Lechuga-Vieco, Ana Victoria
  • Enríquez, José Antonio
  • Núñez, Gabriel
  • Mittelbrunn, María
[Data availability] Ileum RNA-sequencing raw data, as well as microbiota 16S rRNA gene sequencing raw data, are publicly available via NCBI with BioProject numbers PRJNA1301342 and PRJNA1291203, respectively., Mitochondrial diseases progressively lead to multisystemic failure with treatment options remaining extremely limited. Here, to investigate strategies that alleviate mitochondrial dysfunction, we first generate a ubiquitous and tamoxifen-inducible knockout mouse model of mitochondrial transcription factor A (TFAM), a nuclear-encoded protein involved in mitochondrial DNA (mtDNA) maintenance — Tfamfl/flUbcCre-ERT2 (iTfamKO) mice. Systemic TFAM deficiency triggers mitochondrial decline in a myriad of tissues in adult mice. Consequently, iTfamKO mice manifest multiorgan dysfunction including lipodystrophy, sarcopenia, metabolic alterations, kidney failure, neurodegeneration, and locomotor dysregulation, which result in the premature death of these mice. Interestingly, iTfamKO mice display intestinal barrier disruption and gut dysbiosis, with diminished levels of microbiota-derived short-chain fatty acids (SCFAs), such as butyrate. Mice with a deficient proof-reading version of the mtDNA polymerase gamma (mtDNA-mutator mice) phenocopy the dysfunction of the intestinal barrier and bacterial dysbiosis with reduced levels of butyrate, suggesting that different mouse models of mitochondrial dysfunction share insufficient generation of butyrate. Transfer of microbiota from healthy control mice or administration of tributyrin, a butyrate precursor, delay multiple signs of multimorbidity, extending lifespan in iTfamKO mice. Mechanistically, butyrate supplementation recovers epigenetic histone acylation marks that are lost in the intestine of Tfam deficient mice. Overall, our findings highlight the relevance of preserving host-microbiota symbiosis in disorders related to mitochondrial dysfunction., We thank the Oxford Hospitals charity and Lily Foundation “Treatments for Mitochondrial Disease – 2019/20” (J.P.), Fundación Ramón Areces and MINECO through the Centers of Excellence Severo Ochoa Award, and CERCA Programme of the Generalitat de Catalunya (A.V.L.-V.). Funded by the European Union (M.M.). Views and opinions expressed are, however, those of the authors only and do not necessarily reflect those of the European Union or the European Research Council Executive Agency. Neither the European Union nor the granting authority can be held responsible for them. This research was supported by a European Research Council grant ERC-2021-CoG 101044248-Let T Be (M.M.), Comunidad de Madrid (Spain) grant Y2020/BIO-6350 NutriSION-CM synergy (E.C. and M.M.), Spanish Ministerio de Ciencia e Innovación grant PID2022-141169OB-I00 (M.M.), Comunidad de Madrid (Spain) – Universidad Autónoma de Madrid (UAM) grant SI4/PJI/2024-00166 (E.C.), NIH grant R01 DK095782 (G.N.), Ministerio de Ciencia, Innovación y Universidades (Spain) FPU grants FPU19/02576 (M.M.G.H.), FPU24/02492 (P.R.-R.) and FPU20/04066 (J.I.E.-L.), Comunidad de Madrid (Spain) PIPF grant PIPF-2022/SAL-GL-25208 (S.D.-P.), Universidad Autónoma de Madrid FPI-UAM grant (G.S.-H.), and Ministerio de Ciencia, Innovación y Universidades (Spain) Juan de la Cierva-Incorporación grants IJC2018-036850-I (E.G.-R.) and JC2020-044392-I (I.F.-Q.)., Peer reviewed